Trouble reading this email? View it in your browser
European Federation of Pharmaceutical Industries and Associations EFPIA Newsletter 07 May 2026
      Why cardiovascular health checks: The case for EU action
 
 
Learn more here.
 

Cardiovascular diseases (CVDs) account for approximately 1.7 million deaths each year, affect around 62 million people, and generate economic costs exceeding EUR 282 billion annually. Early detection and prevention should be viewed as long term investments in health system sustainability. 

To effectively address this pressing burden, in December 2025 the European Commission launched the EU Safe Hearts Plan. The proposal for a Council Recommendation on health checks is a core component of the Safe Hearts Plan.

This is a golden opportunity to step up early detection, improve outcomes across the EU, and save costs for health systems and societies.  

Read more →
 
 
      ONE Vision: a "North Star" for a future-ready regulatory system

Europe’s regulatory system for medicines is one of the most scientifically rigorous and respected in the world. As science advances and new types of therapies emerge, ensuring the system continues to evolve will be key to bringing innovation to European patients faster. 

In a new article published by Pink Sheet / Citeline, EFPIA outlines ONE Vision – a proposal for a future-ready regulatory framework. 

Read the full article here.

 
 
      Events
 
 
08 MAY 2026
  Unlocking Europe’s Life Science potential: A policy agenda for competitiveness, innovation... The Landmark Nicosia, Cyprus

Europe stands at a critical moment for its life sciences sector. Across the world, governments are actively strengthening...

Learn more →
 
 
 
12 MAY 2026
  EFGCP Conference 2026 Brussels, Hybrid

Join the EFGCP Conference 2026 in Brussels to explore how ethical review systems can strengthen Europe’s clinical research...

Learn more →
 
 
 
19 MAY 2026
  European Pharmaceutical Law Forum Brussels, Belgium

The European pharmaceutical market is facing a moment of profound change. With sweeping updates to the EU pharmaceutical...

Learn more →
 
 
 
03 JUN 2026
  European Conference on Rare Diseases and Orphan Products (ECRD) 2026 Prague & Online

The next ECRD will be held on 3 & 4 June 2026 in Prague and will be titled “Rare Diseases in a Changing & Competitive...

Learn more →
 
 
      What we are reading
Could the EU use public health data to follow the US single-trial policy? 06 May 2026  (Pink Sheet ) Read more →
Government renews call to Europe for pharmaceutical taskforce 05 May 2026  (RTE) Read more →
Brussels pushes to wrap up ‘last’ health files as biotech gap looms 05 May 2026  (Euractiv) Read more →
Faster Dutch research system needed to stop clinical trial decline 30 April 2026  (Euractiv) Read more →
    About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

 
Tel: +32 (0)2 626 25 55
Communications@efpia.eu
in
 
EFPIA 2026 All rights reserved  ·  Disclaimer  ·  Unsubscribe